focus -WSS

focus

author：focus 2025-09-30 06:21:55 - browse：573

Eli Lilly said Friday it will acquire Versanis Bio, a private company developing an obesity drug that specifically targets fat mass, as the race among pharmaceutical companies to offer weight loss medications intensifies.

The deal indicates Lilly is aiming to diversify its growing portfolio of weight loss therapies, as Versanis’ drug employs an entirely different mechanism than the existing obesity drugs that Lilly is studying. The pharma giant didn’t say how much it would pay Versanis upfront, but said that if the drug meets certain milestones, the total payment could reach $1.9 billion.

Lilly, along with other pharma companies like Novo Nordisk, has been developing products in the class of GLP-1 drugs, which mimic the glucagon-like peptide 1 hormone that helps people feel full. These drugs – including Novo’s Ozempic and Wegovy, and Lilly’s Mounjaro – have exploded in popularity because they lead to significant weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Alabama frozen embryo ruling has major implications for IVF clinics

hotspot

entertainment

WSS

Obesity drugs seen as possible treatment for liver disease MASH

PBM reform efforts get punted in Congress

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

The Harvard botanist who searched for psychedelics in the Amazon

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Medicare inequities exacerbate Puerto Rico’s health disparities

Wikipedia

focus

entertainment

Peter Hotez and the public health issue of online harassment

Anthony Fauci pushes back on GOP claims during Covid hearing

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

The Harvard botanist who searched for psychedelics in the Amazon

In Memoriam: Notable people who died in 2023

ASCO Takeaways: Winners, snoozers, and the art of cancer care

Hollywood unions extend contract negotiations for actors

Stopping antidepressants leads to symptoms for 1 in 6 patients

BioMarin wins approval for gene therapy to treat hemophilia A

Medicare inequities exacerbate Puerto Rico’s health disparities

focus

FDA approves Moderna’s RSV vaccine, its second licensed product

A solution to the after

NIH study of ME/CFS points to clear biological hallmarks

Alabama frozen embryo ruling has major implications for IVF clinics

Senators tussle over abortion against the backdrop of a presidential campaign

ASCO Daily Recap: CAR

leisure time

hotspot

entertainment

hotspot